

# Benjamin M Scirica

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5790638/benjamin-m-scirica-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

115  
papers

7,674  
citations

34  
h-index

87  
g-index

125  
ext. papers

9,151  
ext. citations

10.5  
avg, IF

5.55  
L-index

#	Paper	IF	Citations
115	Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program. <i>American Heart Journal</i> , <b>2022</b> , 243, 15-27	4.9	0
114	The Doctor Is Out—New Tactics and Soldiers for Our Losing Battle Against Hypertension. <i>Circulation</i> , <b>2022</b> , 145, 1629-1631	16.7	1
113	Workflow Automation for a Virtual Hypertension Management Program. <i>Applied Clinical Informatics</i> , <b>2021</b> , 12, 1041-1048	3.1	2
112	Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial). <i>PLoS ONE</i> , <b>2021</b> , 16, e0259372	3.7	0
111	Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers. <i>Respiratory Research</i> , <b>2021</b> , 22, 272	7.3	
110	Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e021412	6	0
109	The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial. <i>International Journal of COPD</i> , <b>2021</b> , 16, 689-699	3	
108	Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2P-TIMI 50. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e018673	6	3
107	Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e017401	6	6
106	Evaluation of the Usage and Dosing of Guideline-Directed Medical Therapy for Heart Failure With Reduced Ejection Fraction Patients in Clinical Practice. <i>Journal of Pharmacy Practice</i> , <b>2021</b> , 8971900211004840	1.3	0
105	Hypertensive Heartbreak. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 2145-2152	59.2	
104	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 129-139	59.2	243
103	Digital Care Transformation: Interim Report From the First 5000 Patients Enrolled in a Remote Algorithm-Based Cardiovascular Risk Management Program to Improve Lipid and Hypertension Control. <i>Circulation</i> , <b>2021</b> , 143, 507-509	16.7	16
102	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , <b>2021</b> , 143, 470-478	16.7	13
101	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. <i>Circulation</i> , <b>2021</b> , 143, 685-695	16.7	3
100	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. <i>Circulation Genomic and Precision Medicine</i> , <b>2021</b> , 14, e003006	5.2	1
99	Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial. <i>Advances in Therapy</i> , <b>2021</b> , 38, 5381-5397	4.1	

98	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. <i>Diabetes Care</i> , <b>2021</b> , 44, 2573-2581	14.6	0
97	MRI-EEG correlation for outcome prediction in postanoxic myoclonus: A multicenter study. <i>Neurology</i> , <b>2020</b> , 95, e335-e341	6.5	6
96	Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 1095-1106	15.1	12
95	Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. <i>American Journal of Cardiology</i> , <b>2020</b> , 125, 1577-1581 <sup>1</sup>		
94	Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2P-TIMI 50 trial. <i>Vascular Medicine</i> , <b>2020</b> , 25, 124-132	3.3	15
93	Rationale and design of a navigator-driven remote optimization of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction. <i>Clinical Cardiology</i> , <b>2020</b> , 43, 4-13	3.3	8
92	Racial and Ethnic Disparities in Postcardiac Arrest Targeted Temperature Management Outcomes. <i>Critical Care Medicine</i> , <b>2020</b> , 48, 56-63	1.4	3
91	NT-proBNP: Can We Better Utilize Biomarkers in Patients With Diabetes?. <i>Diabetes Care</i> , <b>2020</b> , 43, 2904-2905	2.0	2
90	Practice pattern of use of high sensitivity troponin in the outpatient settings. <i>Clinical Cardiology</i> , <b>2020</b> , 43, 1573-1578	3.3	1
89	Remote Optimization of Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 1430-1434	16.2	19
88	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , <b>2019</b> , 140, 1569-1577	16.7	57
87	Impact of a Multidisciplinary Treatment Pathway for Atrial Fibrillation in the Emergency Department on Hospital Admissions and Length of Stay: Results of a Multi-Center Study. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e012656	6	9
86	Effect of Acclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 321, 1693-1701	27.4	20
85	Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2P-TIMI 50 trial. <i>Vascular Medicine</i> , <b>2019</b> , 24, 159-161	3.3	3
84	Implementation of an Emergency Department High-Sensitivity Troponin Chest Pain Pathway in the United States. <i>Critical Pathways in Cardiology</i> , <b>2019</b> , 18, 1-4	1.3	2
83	Quantitative EEG reactivity and machine learning for prognostication in hypoxic-ischemic brain injury. <i>Clinical Neurophysiology</i> , <b>2019</b> , 130, 1908-1916	4.3	26
82	Phenotyping to Facilitate Accrual for a Cardiovascular Intervention. <i>Journal of Clinical Medicine Research</i> , <b>2019</b> , 11, 458-463	2.9	3
81	Extending i2b2 into a framework for semantic abstraction of EHR to facilitate rapid development and portability of Health IT applications. <i>AMIA Summits on Translational Science Proceedings</i> , <b>2019</b> , 2019, 370-378	1.1	2

80	Quantitative Electroencephalogram Trends Predict Recovery in Hypoxic-Ischemic Encephalopathy. <i>Critical Care Medicine</i> , <b>2019</b> , 47, 1416-1423	1.4	11
79	Development of an entirely remote, non-physician led hypertension management program. <i>Clinical Cardiology</i> , <b>2019</b> , 42, 285-291	3.3	22
78	Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. <i>Circulation</i> , <b>2019</b> , 139, 366-375	16.7	21
77	Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. <i>Circulation</i> , <b>2019</b> , 139, 1384-1395	16.7	115
76	Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 47, 353-360	5.1	6
75	Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). <i>American Journal of Cardiology</i> , <b>2019</b> , 123, 145-152	3	16
74	Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2 <sup>®</sup> P-TIMI 50 Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2019</b> , 2048872619883354	4.3	2
73	Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk. <i>European Heart Journal</i> , <b>2018</b> , 39, 2255-2262	9.5	28
72	Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. <i>American Heart Journal</i> , <b>2018</b> , 202, 39-48	4.9	12
71	Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy. <i>European Heart Journal</i> , <b>2018</b> , 39, 193-200	9.5	3
70	Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. <i>American Heart Journal</i> , <b>2018</b> , 202, 54-60	4.9	3
69	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1107-1117	59.2	143
68	Combination of Clinical Exam, MRI and EEG to Predict Outcome Following Cardiac Arrest and Targeted Temperature Management. <i>Neurocritical Care</i> , <b>2018</b> , 29, 396-403	3.3	16
67	Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2018</b> , 5, 5-15	2.7	6
66	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. <i>Lancet, The</i> , <b>2018</b> , 392, 2269-2279	4.0	46
65	Extraction of Ejection Fraction from Echocardiography Notes for Constructing a Cohort of Patients having Heart Failure with reduced Ejection Fraction (HFrEF). <i>Journal of Medical Systems</i> , <b>2018</b> , 42, 209	5.1	13
64	Serum potassium levels, cardiac arrhythmias, and mortality following non-ST-elevation myocardial infarction or unstable angina: insights from MERLIN-TIMI 36. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2017</b> , 6, 18-25	4.3	23
63	Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2 <sup>®</sup> P-TIMI 50 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2017</b> , 6, 164-172	4.3	7

62	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2017</b> , 10, 1105-1114	6.4	94
61	Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. <i>Diabetes Research and Clinical Practice</i> , <b>2017</b> , 130, 24-33	7.4	14
60	Delayed Deterioration of EEG Background Rhythm Post-cardiac Arrest. <i>Neurocritical Care</i> , <b>2017</b> , 26, 411-419	3.5	10
59	Use of Biomarkers in Predicting the Onset, Monitoring the Progression, and Risk Stratification for Patients with Type 2 Diabetes Mellitus. <i>Clinical Chemistry</i> , <b>2017</b> , 63, 186-195	5.5	24
58	High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2 <sup>®</sup> P - TIMI 50 Trial. <i>Clinical Chemistry</i> , <b>2017</b> , 63, 307-315	5.5	16
57	The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1390-1400	12.3	111
56	Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , <b>2017</b> , 40, 69-76	14.6	162
55	Outcomes in patients undergoing percutaneous ventricular assist device implantation for cardiogenic shock. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2016</b> , 5, 108-16	4.3	12
54	Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. <i>Circulation</i> , <b>2016</b> , 134, 304-13	16.7	102
53	Beatquency domain and machine learning improve prediction of cardiovascular death after acute coronary syndrome. <i>Scientific Reports</i> , <b>2016</b> , 6, 34540	4.9	13
52	Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2 <sup>®</sup> P-TIMI 50). <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 1055-8	3	4
51	Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2 <sup>®</sup> P-TIMI 50). <i>Circulation</i> , <b>2016</b> , 133, 1007-1015	16.7	120
50	Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 340.e1-8	2.4	27
49	Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non-ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5, e002784	6	3
48	Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , <b>2016</b> , 39, 1329-37	14.6	11
47	Long-Term Post-Discharge Risks in Older Survivors of Myocardial Infarction With and Without Out-of-Hospital Cardiac Arrest. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 1981-90	15.1	21
46	Effect of stimulus type and temperature on EEG reactivity in cardiac arrest. <i>Clinical Neurophysiology</i> , <b>2016</b> , 127, 3412-3417	4.3	21
45	Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	30

44	Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 <sup>PP</sup> )-TIMI 50. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	12
43	Continuous electrodermal activity as a potential novel neurophysiological biomarker of prognosis after cardiac arrest--A pilot study. <i>Resuscitation</i> , <b>2015</b> , 93, 128-35	4	14
42	Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. <i>Europace</i> , <b>2015</b> , 17, 32-7	3.9	40
41	Cardiac arrest and clinical characteristics, treatments and outcomes among patients hospitalized with ST-elevation myocardial infarction in contemporary practice: A report from the National Cardiovascular Data Registry. <i>American Heart Journal</i> , <b>2015</b> , 169, 515-22.e1	4.9	28
40	Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. <i>Diabetes Care</i> , <b>2015</b> , 38, 1145-53	14.6	61
39	Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , <b>2015</b> , 3, 356-66	18.1	193
38	Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , <b>2015</b> , 38, 2142-50	14.6	46
37	Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". <i>Circulation</i> , <b>2015</b> , 132, e121-2	16.7	45
36	Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2 <sup>PP</sup> -TIMI 50. <i>Circulation</i> , <b>2015</b> , 132, 1871-9	16.7	30
35	Response to Letter Regarding Article, "Surgical Ineligibility and Mortality Among Patients With Unprotected Left Main or Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention". <i>Circulation</i> , <b>2015</b> , 132, e156	16.7	2
34	Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 Trial. <i>Clinical Cardiology</i> , <b>2015</b> , 38, 469-75	3.3	15
33	The Association of Previous Revascularization With In-Hospital Outcomes in Acute Myocardial Infarction Patients: Results From the National Cardiovascular Data Registry. <i>JACC: Cardiovascular Interventions</i> , <b>2015</b> , 8, 1954-1962	5	9
32	Evaluation of glucose management during therapeutic hypothermia at a Tertiary Academic Medical Center. <i>Resuscitation</i> , <b>2015</b> , 89, 64-9	4	6
31	Long-term management and unmet needs after an acute coronary syndrome event. <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 29A-35A	3	2
30	Extracorporeal membrane oxygenation in adults with cardiogenic shock. <i>Circulation</i> , <b>2015</b> , 131, 676-80	16.7	41
29	Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. <i>Heart</i> , <b>2014</b> , 100, 1762-9	5.1	34
28	Surgical ineligibility and mortality among patients with unprotected left main or multivessel coronary artery disease undergoing percutaneous coronary intervention. <i>Circulation</i> , <b>2014</b> , 130, 2295-301	16.7	82
27	Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosis. <i>European Journal of Preventive Cardiology</i> , <b>2014</b> , 21, 1531-40	3.9	11

26	Relation of T-wave alternans to mortality and nonsustained ventricular tachycardia in patients with non-ST-segment elevation acute coronary syndrome from the MERLIN-TIMI 36 trial of ranolazine versus placebo. <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 17-23	3	16
25	Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 1317-26	59.2	2459
24	Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. <i>Circulation</i> , <b>2013</b> , 127, 1522-9, 1529e1-6	16.7	208
23	Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 <sup>P</sup> -TIMI 50 trial. <i>Lancet, The</i> , <b>2012</b> , 380, 1317-24	4 <sup>0</sup>	177
22	Vorapaxar in the secondary prevention of atherothrombotic events. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 1404-13	59.2	694
21	The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 57, 1888-19	15.1	101
20	Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. <i>European Heart Journal</i> , <b>2011</b> , 32, 697-705	9.5	64
19	Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. <i>Circulation</i> , <b>2010</b> , 122, 455-62	16.7	88
18	Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. <i>European Heart Journal</i> , <b>2010</b> , 31, 1993-2005	9.5	43
17	Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. <i>Clinical Chemistry</i> , <b>2009</b> , 55, 265-73	5.5	45
16	Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. <i>American Heart Journal</i> , <b>2009</b> , 158, 335-341 e3	4.9	157
15	Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 53, 1000-10	15.1	39
14	Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. <i>Circulation</i> , <b>2007</b> , 116, 1647-52	16.7	360
13	Ranolazine in patients with angina and coronary artery disease. <i>Current Cardiology Reports</i> , <b>2007</b> , 9, 272-8	4.2	12
12	A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study. <i>European Heart Journal</i> , <b>2007</b> , 28, 2070-6	9.5	7
11	Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. <i>Clinical Chemistry</i> , <b>2007</b> , 53, 1800-7	5.5	63
10	Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 297, 1775-83	27.4	372
9	Appropriate invasive and conservative treatment approaches for patients with non-ST-elevation MI. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2006</b> , 8, 13-21	2.1	

8	Valvular heart disease in pregnancy. <i>Current Cardiology Reports</i> , <b>2006</b> , 8, 83-9	4.2	5
7	Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. <i>Circulation</i> , <b>2006</b> , 113, 2128-34; discussion 2151	16.7	153
6	Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. <i>American Heart Journal</i> , <b>2006</b> , 151, 1186.e1-9	4.9	56
5	Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2006</b> , 22, 95-102	5.1	13
4	Treatment of elevated cholesterol. <i>Circulation</i> , <b>2005</b> , 111, e360-3	16.7	16
3	Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. <i>American Journal of Cardiology</i> , <b>2002</b> , 90, 303-5	3	63
2	Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification. <i>American Journal of Cardiology</i> , <b>2002</b> , 90, 821-6	3	15
1	Assessing the effect of publication of clinical guidelines on the management of unstable angina and non-ST elevation myocardial infarction in the TIMI III (1990-1993) and the GUARANTEE (1995-1996) Registries. <i>Critical Pathways in Cardiology</i> , <b>2002</b> , 1, 150-8	1.3	2